Reuters) - Danish pharmaceuticals group Lundbeck (LUN.CO) and Belgium’s Solvay (SOLB.BR) halted development of an experimental schizophrenia drug after receiving disappointing data from a clinical trial.
Reuters) - Danish pharmaceuticals group Lundbeck (LUN.CO) and Belgium’s Solvay (SOLB.BR) halted development of an experimental schizophrenia drug after receiving disappointing data from a clinical trial.